Last reviewed · How we verify
NCT05298046
Study of TAVO101 in Healthy Volunteers
Phase 1 trial testing Experimental: TAVO101 in Healthy Subjects in 42 participants. Completed in 30 September 2024.
1 June 2024
Quick facts
| Lead sponsor | Tavotek Biotherapeutics |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 42 |
| Start date | 11 May 2022 |
| Primary completion | 1 June 2024 |
| Estimated completion | 30 September 2024 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- Experimental: TAVO101 — full drug profile →
- Other: Placebo — full drug profile →
Conditions studied
- Healthy Subjects — all drugs for Healthy Subjects →
Sponsor
Tavotek Biotherapeutics — full company profile →
Who can join
Adults 18 to 65, any sex, with Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase 1, single ascending dose study designed to investigate TAVO101, administered as an IV infusion in healthy subjects. This study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAVO101.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Potential of alarmin-targeted bispecific and combination therapies in airway disease.
Komori HK, Ortega H. · · 2025 · PMID 41409758 · DOI 10.3389/falgy.2025.1700060
Verify or expand the search:
- PubMed search for NCT05298046
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy Subjects
Currently open trials in the same condition.
- NCT07222020 — Phase 1 Study of Intravaginal KB15A · Phase 1 · recruiting
- NCT07350538 — The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL · NA · active not recruiting
- NCT07304791 — This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P · Phase 1 · recruiting
- NCT07059858 — Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities · recruiting
- NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting
Other Tavotek Biotherapeutics trials
Trials by the same sponsor.
- NCT06176040 — A Study of TAVO101 in Atopic Dermatitis Patients · Phase 2 · active not recruiting
- NCT06761651 — A Study of TAVO412 in Patients with Cancer (TAVO412) · Phase 1 · recruiting
- NCT05548634 — A Study of TAVO412 in Patients with Cancer · Phase 1 · active not recruiting
- NCT05313152 — Study of TAVO103A in Healthy Volunteers · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05298046 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tavotek Biotherapeutics
- Last refreshed: 19 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05298046.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing